FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289339997> ?p ?o ?g. }

• W4289339997 endingPage "22.e23" @default.
• W4289339997 startingPage "8" @default.
• W4289339997 abstract "BackgroundCurrently, 19 disease-modifying therapies (DMTs) have been approved for the treatment of patients with relapsing forms of multiple sclerosis (RMS).ObjectiveThe objective of this study was to conduct a systematic review and network meta-analysis to evaluate the efficacy and safety of DMTs in adults with RMS.MethodsWe searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, the Food and Drug Administration, and European Medicines Agency websites for randomized controlled trials (RCTs) (from inception to July 2021). Eligible RCTs evaluated approved treatments for RMS as monotherapy and reported at least one of the primary outcome measures of interest. The primary outcome was efficacy (annualized relapse rate and 12-week confirmed disability progression) and safety (serious adverse events [AEs] and discontinuation due to AEs). We assessed the risk of bias (RoB) of included studies using the Cochrane RoB tool version 2.0 (https://www.bmj.com/content/343/bmj.d5928) for RCTs. Surface under the cumulative ranking (SUCRA) was used to rank therapies and to assess quality of general evidence, respectively. The Grading of Recommendations Assessment, Development and Evaluation framework was used to rank therapies and to assess quality of general evidence.ResultsA total of 43 records represent 45 RCTs selected for network meta-analysis. In total, 30,720 participants (median of 732; interquartile range: 248-931) were included, of which 67% were female. By SUCRA analysis, alemtuzumab (94.3%) presented the highest probability of being the best alternative for annualized relapse rate, whereas ofatumumab (93.5%) presented the highest probability of being the best alternative for 12-week confirmed disability progression. Interferon beta-1b subcutaneous (87.0%) presented the highest probability of the best safety among all DMTs for serious AEs, whereas alemtuzumab (92.4%) presented the highest probability of the best safety among all DMTs for discontinuation due to AEs.ConclusionNetwork meta-analysis shows that alemtuzumab and ofatumumab present the highest efficacy among DMTs. Because there is little difference between these probabilities for many treatments, health professionals should use clinical shared decision making when formulating treatment plans with patients." @default.
• W4289339997 created "2022-08-02" @default.
• W4289339997 creator A5008243890 @default.
• W4289339997 creator A5008666872 @default.
• W4289339997 creator A5010463478 @default.
• W4289339997 creator A5026243543 @default.
• W4289339997 creator A5033654496 @default.
• W4289339997 creator A5037101612 @default.
• W4289339997 creator A5049352241 @default.
• W4289339997 creator A5049692186 @default.
• W4289339997 creator A5066301442 @default.
• W4289339997 creator A5066509406 @default.
• W4289339997 creator A5074679354 @default.
• W4289339997 date "2023-01-01" @default.
• W4289339997 modified "2023-10-18" @default.
• W4289339997 title "Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis" @default.
• W4289339997 cites W1512495229 @default.
• W4289339997 cites W1529192025 @default.
• W4289339997 cites W1580917658 @default.
• W4289339997 cites W1666336517 @default.
• W4289339997 cites W1943280741 @default.
• W4289339997 cites W1967838438 @default.
• W4289339997 cites W1973550674 @default.
• W4289339997 cites W1983382084 @default.
• W4289339997 cites W1983999022 @default.
• W4289339997 cites W1987700102 @default.
• W4289339997 cites W1990918979 @default.
• W4289339997 cites W1997880566 @default.
• W4289339997 cites W2005506388 @default.
• W4289339997 cites W2037593179 @default.
• W4289339997 cites W2043591841 @default.
• W4289339997 cites W2055207309 @default.
• W4289339997 cites W2061005334 @default.
• W4289339997 cites W2082285796 @default.
• W4289339997 cites W2089110777 @default.
• W4289339997 cites W2093009907 @default.
• W4289339997 cites W2095707498 @default.
• W4289339997 cites W2103758700 @default.
• W4289339997 cites W2104948944 @default.
• W4289339997 cites W2105159132 @default.
• W4289339997 cites W2105206040 @default.
• W4289339997 cites W2108187859 @default.
• W4289339997 cites W2112165124 @default.
• W4289339997 cites W2115989506 @default.
• W4289339997 cites W2118735809 @default.
• W4289339997 cites W2122545833 @default.
• W4289339997 cites W2125435699 @default.
• W4289339997 cites W2129967156 @default.
• W4289339997 cites W2133329597 @default.
• W4289339997 cites W2139204856 @default.
• W4289339997 cites W2139367012 @default.
• W4289339997 cites W2139560482 @default.
• W4289339997 cites W2143134934 @default.
• W4289339997 cites W2144318111 @default.
• W4289339997 cites W2148766438 @default.
• W4289339997 cites W2151340435 @default.
• W4289339997 cites W2155798268 @default.
• W4289339997 cites W2158202057 @default.
• W4289339997 cites W2166983650 @default.
• W4289339997 cites W2169098250 @default.
• W4289339997 cites W2179093540 @default.
• W4289339997 cites W2267348707 @default.
• W4289339997 cites W2321043971 @default.
• W4289339997 cites W2409482708 @default.
• W4289339997 cites W2552609792 @default.
• W4289339997 cites W2561881161 @default.
• W4289339997 cites W2565433170 @default.
• W4289339997 cites W2592417717 @default.
• W4289339997 cites W2736093189 @default.
• W4289339997 cites W2746013434 @default.
• W4289339997 cites W2746924405 @default.
• W4289339997 cites W2779588463 @default.
• W4289339997 cites W2784859886 @default.
• W4289339997 cites W2790816436 @default.
• W4289339997 cites W2791895280 @default.
• W4289339997 cites W2802139618 @default.
• W4289339997 cites W2884623256 @default.
• W4289339997 cites W2906720084 @default.
• W4289339997 cites W2916040650 @default.
• W4289339997 cites W2954551873 @default.
• W4289339997 cites W2969291495 @default.
• W4289339997 cites W2970684805 @default.
• W4289339997 cites W2971487735 @default.
• W4289339997 cites W2971577153 @default.
• W4289339997 cites W3039664808 @default.
• W4289339997 cites W3047302551 @default.
• W4289339997 cites W3048952843 @default.
• W4289339997 cites W3094115567 @default.
• W4289339997 cites W3099273656 @default.
• W4289339997 cites W3120221274 @default.
• W4289339997 cites W3126526370 @default.
• W4289339997 cites W3149798718 @default.
• W4289339997 cites W3156339338 @default.
• W4289339997 cites W3199105164 @default.
• W4289339997 cites W4236512734 @default.
• W4289339997 cites W4283072982 @default.
• W4289339997 cites W4283079635 @default.
• W4289339997 doi "https://doi.org/10.1016/j.japh.2022.07.009" @default.

• next